Estrella Immunopharma (NASDAQ:ESLA) Upgraded to Hold at Wall Street Zen

Estrella Immunopharma (NASDAQ:ESLA) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

A number of other research firms also recently issued reports on ESLA. D. Boral Capital dropped their price target on Estrella Immunopharma from $16.00 to $8.00 and set a “buy” rating on the stock in a research report on Wednesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Estrella Immunopharma in a research note on Wednesday. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $8.00.

Estrella Immunopharma Stock Performance

Shares of NASDAQ:ESLA opened at $1.12 on Friday. The firm’s 50 day simple moving average is $1.47 and its 200-day simple moving average is $1.42. Estrella Immunopharma has a one year low of $0.73 and a one year high of $3.15. The firm has a market cap of $42.30 million, a PE ratio of -3.29 and a beta of 0.55.

Estrella Immunopharma (NASDAQ:ESLA) last announced its quarterly earnings results on Wednesday, November 12th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.06.

About Estrella Immunopharma

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103.